Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.

Cancer research - 15 Mar 2001

Geisler S, Lønning P E, Aas T, Johnsen H, Fluge O, Haugen D F, Lillehaug J R, Akslen L A, Børresen-Dale A L

Abstract excerpt

TP53 status [mutations, immunostaining, and loss of heterozygosity (LOH)], expression of c-erbB-2, bcl-2, and histological grading were correlated to the response to doxorubicin monotherapy (14 mg/m2) administered weekly to 90 patients with locally advanced breast cancer. Mutations in the TP53 ge...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antineoplastic
Share to Disease-Free Survival
Share to Doxorubicin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, p53

Share to Loss of Heterozygosity

Share to Proto-Oncogene Proteins c-bcl-2

Share to Receptor, ErbB-2

Share to Survival Rate

Source

Identifiers

PMID: 11289122

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-11289122-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.PMID 11289122Read ↗

TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.Semantic proximity Read ↗

A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients.Semantic proximity Read ↗

The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer.Semantic proximity Read ↗

TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.Semantic proximity Read ↗

Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients. Austrian Breast Cancer Study Group.Semantic proximity Read ↗

p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial.Semantic proximity Read ↗

Loss of heterozygosity and p53 gene mutations in breast cancer.Semantic proximity Read ↗

Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.